van Ommen – Nijhof A, Steenbruggen TG, Schats W, et al. - Researchers assessed factors related to long-term survival in patients with oligometastatic breast cancer (OMBC), by performing this systematic review. Studies involving OMBC patients treated with a combination of local and systemic therapy as multimodal approach and describing overall survival (OS) or progression-free survival (PFS), or both, were considered eligible for inclusion. The 5-year OS and 5-year PFS ranged between 30-79% and between 25-57%, respectively. Better outcome was reported in relation to factors such as a solitary metastasis, > 24 months interval between primary tumor and OMBC, no or limited involved axillary lymph nodes at primary diagnosis, and hormone-receptor positivity. HER2 (human epidermal growth factor receptor 2)-positivity was shown to be related to worse outcome, but only few patients were treated with anti-HER2 therapy. Overall, the best OS was reported in OMBC patients with a solitary distant metastasis and > 24 months disease-free interval and these patients may represent optimal candidates to consider a multidisciplinary approach.